Evidence map›Paper›PMID 40491684›Full record

ArticleRespiratory medicine case reports2025

Response of EGFR-mutated pulmonary pleomorphic carcinoma to pembrolizumab.

Yuki Hatakeyama, Hidenori Mizugaki, Noriyuki Yamada, Yasushi Mizukami, Ken Kuwahara, Hajime Asahina, Hirofumi Adachi, Hiroshi Yokouchi, Yoshihiro Matsuno, Satoshi Oizumi

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Respiratory medicine case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yuki HatakeyamaDepartment of Respiratory Medicine, NHO Hokkaido Cancer Center, Sapporo, Japan.
Hidenori MizugakiDepartment of Respiratory Medicine, NHO Hokkaido Cancer Center, Sapporo, Japan.
Noriyuki YamadaDepartment of Respiratory Medicine, NHO Hokkaido Cancer Center, Sapporo, Japan.
Yasushi MizukamiDepartment of Thoracic Surgery, NHO Hokkaido Cancer Center, Sapporo, Japan.
Ken KuwaharaDepartment of Diagnostic Pathology, NHO Hokkaido Cancer Center, Sapporo, Japan.
Hajime AsahinaDepartment of Respiratory Medicine, NHO Hokkaido Cancer Center, Sapporo, Japan.
Hirofumi AdachiDepartment of Thoracic Surgery, NHO Hokkaido Cancer Center, Sapporo, Japan.
Hiroshi YokouchiDepartment of Respiratory Medicine, NHO Hokkaido Cancer Center, Sapporo, Japan.
Yoshihiro MatsunoDepartment of Diagnostic Pathology, NHO Hokkaido Cancer Center, Sapporo, Japan.
Satoshi OizumiDepartment of Respiratory Medicine, NHO Hokkaido Cancer Center, Sapporo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pulmonary pleomorphic carcinoma (PPC) is a rare and aggressive lung malignancy with limited treatment options. While immune checkpoint inhibitors (ICIs) have shown promise in treating PPC, evidence regarding their efficacy in epidermal growth factor receptor (

Indexed as

EGFR mutationImmunotherapyOsimertinibPancoast tumorPD-L1PembrolizumabPleomorphic carcinoma

Identifiers

PMID40491684
PMCPMC12148578

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.